Welcome to our dedicated page for Progyny SEC filings (Ticker: PGNY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Progyny, Inc. filings document public-company reporting for its Nasdaq-listed common stock and its women's health and family building benefits business. Recent Form 8-K reports furnish quarterly and annual financial results, guidance updates, Regulation FD materials, supplemental earnings presentations, and other material-event disclosures.
The company's proxy materials cover annual meeting governance, director and executive compensation, equity award information, and related shareholder voting matters. Other filings address executive employment and compensatory arrangements, as well as a derivative-action settlement notice tied to historical non-employee director compensation practices.
Progyny, Inc. amended a Schedule 13G/A (Amendment No. 4) reporting beneficial ownership information for Kleiner Perkins entities. The cover identifies CUSIP 74340E103 and a reporting date of 03/31/2025. The filing notes zero voting and dispositive power and 0% percent of the class shown on the cover rows. The amendment is signed by Susan Biglieri on 06/05/2026 and includes an Agreement of Joint Filing as Exhibit A.
Progyny, Inc. chief financial officer Mark S. Livingston reported small routine transactions in the company’s common stock. On June 4, 2026, he sold a total of 2,517 shares in open-market trades at $25.50 per share pursuant to a pre-arranged Rule 10b5-1 trading plan. In addition, 1,421 shares were withheld on June 3 and June 4 to cover withholding taxes upon the vesting of restricted stock units. Following these transactions, Livingston directly holds 74,688 shares of Progyny common stock.
Progyny, Inc. executive vice president and general counsel Allison Swartz reported modest net selling of company common stock. She sold a total of 1,798 shares in open-market transactions on June 3–4, 2026 at prices around $25 per share, under a pre-arranged Rule 10b5-1 trading plan. Separate dispositions of 1,015 shares were made to cover withholding taxes upon the vesting of restricted stock units. After these transactions, she directly holds 82,378 shares of Progyny common stock.
Progyny, Inc. CEO Peter Anevski reported routine equity activity related to compensation. On Common Stock, 5,361 shares were disposed of at $25.12 per share as shares were withheld to pay withholding taxes upon the vesting of restricted stock units. Following this tax-withholding disposition, Anevski holds 811,472 shares of Progyny common stock directly, which include 1,111 shares acquired under the company’s 2019 Employee Stock Purchase Plan on January 30, 2026. He also reports an indirect holding of 1 share through PECO ANEVSKI 2020 SD LLC.
PGNY files a Rule 144 notice reporting proposed and recent sales of Common Stock by an affiliate. The filing lists 8,275 shares sold on 05/20/2026 for $211,012.50 and 279 shares sold on 06/02/2026 for $7,309.80. It also lists restricted stock vesting of 1,918 shares on 06/03/2026 and 599 shares on 06/04/2026.
PGNY insider report: Allison Swartz reported dispositions of Common Stock in notices under Rule 144. The filing lists sales of 599 shares on 03/04/2026, 2,398 shares on 05/28/2026, and 1,199 shares on 06/03/2026, with dollar amounts shown for each transaction.
Progyny, Inc.’s Chief Financial Officer Mark S. Livingston reported routine equity transactions in company common stock. He sold 279 shares in an open-market trade at $26.20 per share, executed under a pre-arranged Rule 10b5-1 trading plan entered into on August 15, 2025.
In a separate entry, 158 shares were withheld at $26.20 per share to cover withholding taxes upon the vesting of restricted stock units granted to him. One line shows 78,905 shares owned after the tax-withholding entry, and another shows 78,626 shares owned after the sale.
Progyny director Scott Cheryl exercised stock options to acquire 14,667 shares of Common Stock at $13.00 per share, then sold 7,439 shares in an open-market transaction at about $26.39 per share. The company withheld 7,228 shares to cover tax obligations, and Cheryl now directly holds 19,772 shares.
Progyny, Inc. Chief Product Officer Geoffrey Clapp reported a combination of equity transactions in common stock. He exercised stock options to acquire 12,909 shares at $20.91 per share and sold 1,530 shares in an open-market transaction at $25.58 per share.
In a separate move, 11,379 shares were withheld to cover withholding taxes upon the vesting of restricted stock units granted to him. After these transactions, he directly holds 59,117 shares of Progyny common stock and 26,211 stock options that are scheduled to expire on March 16, 2035.
Allison Swartz reported proposed sales of company common stock under a Form 144 notice. The filing lists 1199 shares tied to restricted stock vesting to be sold through Fidelity Brokerage Services LLC on 06/03/2026 as compensation-related shares. The excerpt also shows three prior dispositions in the past three months: 4,657 shares (03/03/2026), 599 shares (03/04/2026), and 2,398 shares (05/28/2026).